Gitlife Biotech Ltd: Revolutionizing Synthetic Biology with CellRepo

Gitlife Biotech Ltd, a Newcastle University spinout, is paving the way for the future of synthetic biology with their groundbreaking product, CellRepo. Stemming from the innovative research project, Endroid, GitLife Biotech focuses on developing bio-nano safety and cybersecurity that harness the potential of DNA information storage, synthetic biology, and cryptography.

The core mission of GitLife Biotech is to set the global standard in the management of provenance and integrity for biological assets, thereby realising the potential of synthetic biology worldwide. Their flagship product, CellRepo, is the world’s first Version Control System for Synthetic Biology. It ensures the secure ownership, provenance, and traceability of proprietary biological assets, paving the way for effective collaboration among various entities, including governments, businesses, academia, and NGOs.

With the increasing importance of synthetic biology in various industries, the company’s proprietary DNA Barcodes provide much-needed transparency and trustworthiness from the creation to the end-of-life for engineered cell lines. By integrating advances in gene synthesis techniques and the growing convergence of life sciences with informatics, IoT, and automation, GitLife Biotech aims to accelerate the production and consumption of biological products.

The talented team behind GitLife Biotech includes CEO George Neville-Jones, CTO Natalio Krasnogor, CSO Nadia Rostami, and CDO Leanne Hobbs. Together, they are driving innovation and standardisation in the rapidly evolving field of synthetic biology, ultimately pushing the boundaries of what’s possible in the digital economy.

Click here to learn more about GitLife Biotech Ltd.

Image by Gerd Altmann from Pixabay